The Annals
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 37, No. 12, pp. 1904-1908. DOI 10.1345/aph.1D101
© 2003 Harvey Whitney Books Company.
This Article
Right arrow Abstract Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ferrone, M.
Right arrow Articles by Motl, S. E
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ferrone, M.
Right arrow Articles by Motl, S. E

OBJECTIF: Evaluer le trastuzumab dans le traitement des cancers bronchiques non à petites cellules (CBNPC) avancés.

REVUE DE LITTÉRATURE: Littérature clinique obtenue à partir de MEDLINE, d'Embase, d'IPA, des comptes-rendus de la Société américaine d'oncologie clinique, et de Genentech.

RÉSUMÉ: La recherche a mis en évidence que des spécimens de CBNPC étaient susceptibles d'exprimer la protéine HER-2/neu. L'anticorps monoclonal dirigé contre HER-2/neu, le trastuzumab, pourrait se révéler utile pour les patients concernés. Il a été conduit une évaluation des études relatives à l'emploi du trastuzumab dans la prise en charge des CBNPC.

CONCLUSIONS: Les données cliniques issues de certains essais de phase 2 montrent des résultats encourageants quand le trastuzumab est associé à une chimiothérapie de référence. Le bénéfice final dans les CBNPC reste à prouver.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
E. S. Henson, X. Hu, and S. B. Gibson
Herceptin Sensitizes ErbB2-Overexpressing Cells to Apoptosis by Reducing Antiapoptotic Mcl-1 Expression
Clin. Cancer Res., February 1, 2006; 12(3): 845 - 853.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. Rosell
Toward Customized Trastuzumab in HER-2/neu-Overexpressing Non-Small-Cell Lung Cancers
J. Clin. Oncol., April 1, 2004; 22(7): 1171 - 1173.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ferrone, M.
Right arrow Articles by Motl, S. E
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ferrone, M.
Right arrow Articles by Motl, S. E

homecopy help contact us subscription past issues search current issue
Copyright © 2003 by Harvey Whitney Books Company.